Oklahoma 2024 2024 Regular Session

Oklahoma Senate Bill SB217 Introduced / Bill

Filed 01/09/2023

                     
 
 
Req. No. 1358 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
STATE OF OKLAHOMA 
 
1st Session of the 59th Legislature (2023) 
 
SENATE BILL 217 	By: Hamilton 
 
 
 
 
 
AS INTRODUCED 
 
An Act relating to health care; requiring licensed 
practitioners to offer pharmacogenomic test prior to 
prescription of psyc hotropic drugs; requiring certain 
disclosures and obtainment of informed consent; 
directing order and administration of pharmacogenomic 
test; providing for codificat ion; and providing an 
effective date. 
 
 
 
 
 
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOM A: 
SECTION 1.     NEW LAW     A new section of law to be codified 
in the Oklahoma Statutes as Section 7201 of Title 63, unless there 
is created a duplication in numbering, reads a s follows: 
A.  A licensed practitioner shall, prior to the prescription of 
any psychotropic drug to a patient, offer to administer a 
pharmacogenomic test to the patien t for the purpose of guiding the 
decisions of the licensed practitioner with respect to how the 
patient’s genes may react to certain medicat ions. 
B. The licensed practitioner shall , to the best of the licensed 
practitioner’s knowledge, inform the patient of the efficacy of 
pharmacogenomic testing. The licensed practitioner shall inform the   
 
 
Req. No. 1358 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
patient of whether or not the pharmacogenomic test to be 
administered is approved by the Food and Drug Administration. The 
licensed practitioner shall obtain the patient ’s informed consent 
prior to ordering a pharmacogenomic test. If the practitioner is 
aware of the cost of the pharmacogenomic test, the practitioner 
shall provide an estimate to the patient of such cost. 
C. If a patient provides informed consent to receive a 
pharmacogenomic test, the lic ensed practitioner shall o rder the 
pharmacogenomic test and administer such test to the patient prior 
to the prescription of any psychotropic medication . 
SECTION 2.  This act shall become effective November 1, 202 3. 
 
59-1-1358 DC 1/9/2023 5:41:08 PM